M. Powell

发表

M. Powell, 2010, International Journal of Gynecologic Cancer.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

H. Putter, C. Haie-meder, H. Kitchener, 2018, The Lancet. Oncology.

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

H. Putter, C. Haie-meder, H. Kitchener, 2016, The Lancet. Oncology.

Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3 An Intergroup trial of the Dutch Cooperative Gynecologic Oncology Group and the UK National Cancer Research Institute

H. Kitchener, H. Hollema, J. Ledermann, 2007 .

Coronary artery brachytherapy.

T. Warner, M. Rothman, M. Powell, 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: Taking Endometrial Cancer Trials Into the Translational Era

H. Kitchener, P. Goodfellow, M. Birrer, 2013, International Journal of Gynecologic Cancer.

Continuous hyperfractionated accelerated radiotherapy (CHART) in localized cancer of the esophagus.

P. Hoskin, S. Dische, M. Saunders, 1997, International journal of radiation oncology, biology, physics.

482 Experience of a dose escalation study using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekendless) in non-small cell lung cancer

P. Hoskin, M. Saunders, M. Curie, 1997 .

Hysterectomy for patients with locally advanced cervical cancer after primary radiotherapy and/or chemotherapy

A. Bryant, D. Oram, M. Powell, 2013 .

Radiation hazards in pregnancy and methods of prevention.

S. Needleman, M. Powell, 2016, Best practice & research. Clinical obstetrics & gynaecology.

HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes

H. Mackay, Naveena Singh, T. Bosse, 2020, Cancers.

Human tumor blood flow is enhanced by nicotinamide and carbogen breathing.

P. Hoskin, S. Hill, M. Saunders, 1997, Cancer research.

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.

A. Bryant, D. Oram, A. Olaitan, 2022, The Cochrane database of systematic reviews.

Best Practice & Research Clinical Obstetrics and Gynaecology

S. Needleman, M. Powell, 2014 .

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

C. West, C. Dive, Susana Banerjee, 2015, The Lancet. Oncology.

Surgical and Nonsurgical Management of Cervical Cancer: Current Practice and Future Directions

T. Mould, M. Powell, 2017 .

The role of radiotherapy in ovarian cancer

M. Powell, K. Durno, 2022, International Journal of Gynecological Cancer.

NRG Oncology /RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer- An Update.

B. Erickson, W. Bosch, L. Mell, 2020, International journal of radiation oncology, biology, physics.

First quinquennial review of intensity-modulated radiotherapy at St Bartholomew's Hospital, London.

P. Plowman, M. Powell, A. Sibtain, 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

P. Pollock, C. Genestie, H. Kitchener, 2022, Modern Pathology.

Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.

P. Hoskin, M. Stratford, A. Rojas, 1997, British Journal of Cancer.

Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial.

H. Putter, C. Haie-meder, H. Kitchener, 2020, International journal of radiation oncology, biology, physics.

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

P. Pollock, H. Mackay, H. Kitchener, 2015, Modern Pathology.

Tertiary lymphoid structures critical for prognosis in endometrial cancer patients

H. Mackay, T. Bosse, L. Mileshkin, 2021, Nature Communications.

Endometrial cancer

J. McAlpine, E. Crosbie, S. Kitson, 2022, The Lancet.

Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions.

H. Kitchener, D. Carlisle, E. Crosbie, 2016, Gynecologic oncology.

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

H. Putter, C. Haie-meder, P. Pollock, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy.

R. Reznek, A. Rockall, Alexandra Taylor, 2005, International journal of radiation oncology, biology, physics.

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

H. Putter, C. Haie-meder, H. Kitchener, 2019, The Lancet. Oncology.

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

H. Putter, C. Haie-meder, D. Katsaros, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

P. Pollock, H. Kitchener, T. Bosse, 2017, Gynecologic oncology.

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

C. Genestie, H. Mackay, A. Fyles, 2022, British Journal of Cancer.

Endometrial cancer: the individual approach.

M. Powell, 2023, The Lancet Oncology.

Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.

H. Mackay, J. Dijkstra, T. Bosse, 2022, The Lancet. Digital health.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

P. Pollock, C. Genestie, H. Mackay, 2018, Modern Pathology.

LBA25_PRCIRCCA: A RANDOMISED DOUBLE BLIND PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL PLUS CEDIRANIB VERSUS CARBOPLATIN-PACLITAXEL PLUS PLACEBO IN METASTATIC/RECURRENT CERVICAL CANCER. (CRUK GRANT REF: C1256/A11416)

C. West, C. Dive, C. Gourley, 2014 .

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters

H. Mackay, H. Kitchener, H. Hollema, 2015, British Journal of Cancer.

An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition.

A. Rockall, A. Taylor, A Taylor, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

H. Putter, T. Bosse, L. Mileshkin, 2021, Journal of the National Cancer Institute.

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer

H. Mackay, T. Bosse, L. Mileshkin, 2016, Modern Pathology.

Non-Curative Radiotherapy for Bone Metastases

P. Hoskin, M. Powell, 1998 .

Intensity-modulated radiotherapy—what is it?

A. Taylor, A Taylor, M E B Powell, 2004, Cancer imaging : the official publication of the International Cancer Imaging Society.

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.

A. Bryant, D. Oram, E. Brockbank, 2015, The Cochrane database of systematic reviews.

Effect of carbogen breathing on tumour microregional blood flow in humans.

P. Hoskin, S. Hill, P J Hoskin, 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Conformal and intensity-modulated radiotherapy for cervical cancer.

A. Taylor, M. Powell, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.

H. Putter, C. Haie-meder, H. Kitchener, 2017 .

Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations.

P. Hoskin, S. Hill, P J Hoskin, 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A verification study of proposed pelvic lymph node localisation guidelines using nanoparticle-enhanced magnetic resonance imaging.

R. Reznek, A. Rockall, Maria J Vilarino-Varela, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The response of human tumors to carbogen breathing, monitored by Gradient-Recalled Echo Magnetic Resonance Imaging.

J R Griffiths, F A Howe, H Baddeley, 1997, International journal of radiation oncology, biology, physics.

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies

H. Kitchener, T. Bosse, A. Renehan, 2016, Modern Pathology.

An assessment of interfractional uterine and cervical motion: implications for radiotherapy target volume definition in gynaecological cancer.

Alexandra Taylor, Melanie E B Powell, M. Powell, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes.

P. Hoskin, M. Leahy, D. Chaplin, 1996, The British journal of cancer. Supplement.

Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy

C. Haie-meder, P. Pollock, H. Mackay, 2019, Annals of Oncology.

OC-0369: Long-Term Quality of Life after (chemo)radiotherapy for high-risk Endometrial Cancer in PORTEC-3

H. Putter, D. Katsaros, J. Ledermann, 2020 .

Interpretable Deep Learning Predicts the Molecular Endometrial Cancer Classification from H&E Images: A Combined Analysis of the Portec Randomized Clinical Trials

H. Mackay, J. Dijkstra, T. Bosse, 2022, SSRN Electronic Journal.

Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study.

P. Hoskin, S. Dische, J. Denekamp, 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Radiotherapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of Three-Dimensional Conformal Radiotherapy versus Intensity-Modulated Radiotherapy.

H. Putter, C. Haie-meder, H. Kitchener, 2021, International journal of radiation oncology, biology, physics.

Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer.

H Baddeley, H. Baddeley, P. Hoskin, 1999, The British journal of radiology.

Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: Taking Endometrial Cancer Trials Into the Translational Era

H. Kitchener, P. Goodfellow, M. Birrer, 2013, International Journal of Gynecologic Cancer.